GRCL - Gracell Biotechnologies rallies after naming new chief medical officer

• Gracell Biotechnologies ( NASDAQ: GRCL ) announced Monday the appointment of Wendy Li as its new chief medical officer.
• Li brings in over 20 years of experience in pharmaceutical industry across the US and China markets with expertise in leading early- and late-stage clinical trials for several therapeutic candidates for the treatment of hematological malignancies. Prior to joining Gracell, Dr. Li served as CMO of EXUMA Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia.
• "Dr. Li's decades of experience in leading clinical development and strategy across many types of cancers and treatment modalities, as well as expertise in working with regulatory agencies, will be invaluable as we continue to advance our pipeline of breakthrough cell therapies and approach the filing of our U.S. IND application for GC012F later this year," said Dr. William (Wei) Cao, Founder, Chairman and CEO of Gracell.
• Stock is up 23% in premarket trading .
• Earlier: Gracell names Dr. Samuel Zhang as Chief Business Officer

For further details see: